[Parvovirus B19 infection after kidney transplantation]

Area of Science:

• Virology
• Nephrology
• Immunology

Context:

• Human parvovirus B19 infection is a significant concern in renal transplant recipients, with prevalence ranging from 2% to 30%.
• Infection can manifest as primary or reactivation, transmitted via respiratory routes or contaminated grafts/blood products.
• Frequent co-infections with Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) are observed.

Purpose:

• To review the prevalence, transmission, clinical manifestations, diagnosis, and management of human parvovirus B19 infection in renal transplant recipients.
• To highlight the association of parvovirus B19 with renal complications, including graft dysfunction, thrombotic microangiopathies, and collapsing glomerulopathies.
• To discuss diagnostic approaches and therapeutic strategies, emphasizing the role of viral load assessment and immunosuppression modulation.

Summary:

• The hallmark symptom of parvovirus B19 infection is anemia, with potential for pancytopenia and hemophagocytic syndrome.
• Renal involvement occurs in 10% of cases, manifesting as graft dysfunction, thrombotic microangiopathies, or collapsing glomerulopathies, though causality is debated.
• Diagnosis relies on serological status and quantitative PCR for viral load. Treatment involves reduced immunosuppression and intravenous immunoglobulin (IVIG), with a 30% relapse rate.

Impact:

• Provides critical insights for clinicians managing renal transplant recipients, aiding in the early diagnosis and effective treatment of parvovirus B19 infection.
• Contributes to understanding the complex interplay between parvovirus B19 and renal allograft health, potentially improving patient outcomes.
• Informs future research directions regarding the pathogenesis and long-term consequences of parvovirus B19 in immunocompromised populations.